Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment

An initial exacerbation of anxiety can be observed in animals and humans treated with selective serotonin reuptake inhibitors (SSRIs). The neurobiological substrates and mechanism(s) underlying this effect are not clear. We used Fos expression as a marker of neuronal activation to investigate effects of acute fluoxetine treatment in rats submitted to two different models of emotional stress, airjet and immobilization. Exposure to both stressors induced Fos expression in various brain regions implicated in fear/anxiety mechanisms. Acute treatment with 5 mg/kg fluoxetine facilitated airjet-induced escape responses and enhanced the airjet-, as well as immobilization-induced Fos expression exclusively in the locus coeruleus (LC), but not in other areas including the amygdala, hypothalamus or septum. Fluoxetine also facilitated airjet-induced noradrenaline efflux in the medial prefrontal cortex, a projection area of LC noradrenergic neurons. A higher dose of fluoxetine (10 mg/kg) did not change escape responses and had no effect on stress-induced Fos expression in the LC, but decreased airjet-induced Fos expression in the medial amygdala. The results indicate that anxiogenic effects of acute fluoxetine treatment occur in a specific dose range and can be mimicked by exacerbation of escape responses in the airjet model. Furthermore, facilitation of escape responses by fluoxetine is linked to enhanced activity in the LC/noradrenaline system.     

Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation.

Extensive behavioral and biochemical characterization of cannabinoid-mediated effects on the central nervous system has revealed at least three lines of evidence supporting the role of a putative guanine nucleotide-binding protein-coupled cannabinoid receptor for cannabimimetic effects, (i) stereoselectivity, (ii) inhibition of the adenylate cyclase/cAMP second messenger system, and (iii) radioligand-binding studies with the synthetic cannabinoid [3H]CP-55,940 indicating a high degree of specific binding to brain tissue preparations. Based on recent findings from our laboratory demonstrating that delta 9-tetrahydrocannabinol markedly inhibited forskolin-stimulated cAMP accumulation in mouse spleen cells, the presence of a guanine nucleotide-binding protein-coupled cannabinoid receptor associated with mouse spleen cells and its functional role in immune modulation were investigated. In the present studies, stereoselective immune modulation was observed with the synthetic bicyclic cannabinoid (-)-CP-55,940 versus (+) CP-56,667 and with 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl, (-)-HU-210 versus (+)-HU-211. In both cases, the (-)-enantiomer demonstrated greater immunoinhibitory potency than the (+)-isomer, as measured by the in vitro sheep red blood cell antibody-forming cell response. Radioligand binding studies produced a saturation isotherm exhibiting approximately 45-65% specific binding to mouse spleen cells. Scatchard analysis demonstrated a single binding site on spleen cells, possessing a Kd of 910 pM and a Bmax of approximately 1000 receptors/spleen cell. RNA polymerase chain reaction of isolated splenic RNA using specific primers for the cannabinoid receptor resulted in the amplification of a 854-kilobase predicted product that hybridized with cannabinoid receptor cDNA, demonstrating the presence of cannabinoid receptor mRNA in mouse spleen. Together, these findings strongly support the role of a cannabinoid receptor in immune modulation by cannabimimetic agents.     

Bidirectional cannabinoid modulation of social behavior in adolescent rats

Rationale Marijuana use in adolescents is a highly social activity, and interacting endocannabinoid and opioid systems may modulate social reward. However, cannabinoid exposure has been reported to reduce social behavior. Objectives The aim of this study was to elucidate the mechanisms underlying the paradoxical relationship between cannabinoid exposure and sociability. Materials and methods We investigated the effect of cannabinoid agonists with a different mechanism of action on social play behavior in adolescent rats. In addition, we examined whether endocannabinoid neurotransmission interacts with opioid and dopaminergic neurotransmission in the modulation of social play behavior. Results The direct CB₁ cannabinoid receptor agonist WIN55,212-2 reduced social play. However, the indirect cannabinoid agonist URB597, which inhibits the hydrolysis of the endocannabinoid anandamide, enhanced social play. This effect of URB597 depended upon stimulation of opioid and dopamine receptors. The well-known stimulatory effect of morphine on social play was attenuated by the CB₁ cannabinoid receptor antagonist SR141716A, but independent of dopamine receptor stimulation. Combined treatment with ineffective doses of URB597 and morphine increased social play. Conclusions Cannabinoid neurotransmission can both enhance and inhibit social interaction in adolescent rats depending on how the endocannabinoid system is stimulated. Activation of cannabinoid receptors throughout the brain, which occurs during cannabis use, inhibits sociability. In contrast, on-demand release of endocannabinoids facilitates social interaction, which is magnified by indirect cannabinoid agonists through an interaction with opioid and dopaminergic neurotransmission. These results shed light on the paradoxical relationship between cannabis exposure and sociability and suggest that endocannabinoid degradation inhibitors hold promise for the treatment of social dysfunctions.     

Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin

Immunohistofluorescent neurotensin (NT) is found in the ventral tegmental area (VTA), and bilateral injection of NT into the VTA produces an increase in exploratory behaviours. The VTA also contains dopaminergic cell bodies with axonal projections to the nucleus accumbens. In this study it was shown that bilateral microinjection of NT (4.0 μg/side) into the nucleus accumbens blocked the behavioral hyperactivity produced by intra-VTA injection of NT (2.5 μg/side).     

Signaling pathways involved in the development of cannabinoid tolerance

Considerable plasticity exists in the endogenous cannabinoid system, as evidenced by the high degree of tolerance that develops following repetitive exposure to exogenously administered cannabinoid receptor agonists. This tolerance development is accompanied by cannabinoid CB(1) receptor downregulation and attenuation of G-protein activation. The biological processes responsible for CB(1) receptor downregulation remain to be fully understood. However, recent evidence suggests that several protein kinases participate in the development of cannabinoid tolerance. These observations implicate a role for protein kinases in cannabinoid signaling pathways. It remains to be established whether these protein kinases are directly involved in CB(1) receptor regulation or whether they contribute to tolerance by modulating additional signaling pathways.     

Allosteric modulation of the cannabinoid CB1 receptor

We investigated the pharmacology of three novel compounds, Org 27569 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide), Org 27759 (3-ethyl-5-fluoro-1H-indole-2-carboxylic acid [2-94-dimethylamino-phenyl)-ethyl]-amide), and Org 29647 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide, 2-enedioic acid salt), at the cannabinoid CB1 receptor. In equilibrium binding assays, the Org compounds significantly increased the binding of the CB1 receptor agonist [3H]CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol], indicative of a positively cooperative allosteric effect. The same compounds caused a significant, but incomplete, decrease in the specific binding of the CB1 receptor inverse agonist [3H]SR 141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride], indicative of a limited negative binding cooperativity. Analysis of the data according to an allosteric ternary complex model revealed that the estimated affinity of each Org compound was not significantly different when the radioligand was [3H]CP 55,940 or [3H]SR 141716A. However, the estimated cooperatively factor for the interaction between modulator and radioligand was greater than 1 when determined against [3H]CP 55,940 and less than 1 when determined against [3H]SR 141716A. [3H]CP 55,940 dissociation kinetic studies also validated the allosteric nature of the Org compounds, because they all significantly decreased radioligand dissociation. These data suggest that the Org compounds bind allosterically to the CB1 receptor and elicit a conformational change that increases agonist affinity for the orthosteric binding site. In contrast to the binding assays, however, the Org compounds behaved as insurmountable antagonists of receptor function; in the reporter gene assay, the guanosine 5'-O-(3-[35S]thio)triphosphate binding assay and the mouse vas deferens assay they elicited a significant reduction in the Emax value for CB1 receptor agonists. The data presented clearly demonstrate, for the first time, that the cannabinoid CB1 receptor contains an allosteric binding site that can be recognized by synthetic small molecule ligands.     

Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists

An unbiased place preference conditioning procedure was used to examine the secondary reinforcing effects of selective D-1 dopamine (DA) receptor antagonists and the neuroanatomical substrates mediating these effects. Systemic administration of SCH-23390 or the non-benzazepine D-1 receptor antagonist A-69024 produced dose-related conditioned aversions for the drug-associated place. In contrast, the D-2 antagonists spiperone and (–)sulpiride were without effect. SCH-23390-induced place aversions were also observed after intracerebroventricular administration. The minimum dose producing this effect was significantly lower than that after systemic injection. Aversive effects were also observed after microinjection of SCH-23390 into the n. accumbens. In contrast, microinjections of this antagonist into the ventral tegmental area, caudate putamen or medial prefrontal cortex were without effect. These data confirm that the blockade of D-1 but not D-2 DA receptors induces aversive states. Furthermore, they suggest that D-1 receptors in the n. accumbens may play an important role in the regulation of non-drug induced affective states.     

CB1 cannabinoid receptor-mediated modulation of food intake in mice

1 Marijuana's appetite-increasing effects have long been known. Recent research suggests that the CB(1) cannabinoid receptor antagonist SR141716A may suppress appetite. This study represents a further, systematic investigation of the role of CB(1) cannabinoid receptors in the pharmacological effects of cannabinoids on food intake. 2 Mice were food-restricted for 24 h and then allowed access to their regular rodent chow for 1 h. Whereas the CB(1) antagonist SR141716A dose-dependently decreased food consumption at doses that did not affect motor activity, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increased food consumption at doses that had no effect on motor activity. O-3259 and O-3257, structural analogs of SR141716A, produced effects similar to those of the parent compound. 3 Amphetamine (a known anorectic) and diazepam (a benzodiazepine and CNS depressant) decreased food consumption, but only at doses that also increased or decreased motor activity, respectively. The CB(2) cannabinoid receptor antagonist SR144528 and the nonpsychoactive cannabinoid cannabidiol did not affect food intake nor activity. 4 SR141716A decreased feeding in wild-type mice, but lacked pharmacological activity in CB(1) knockout mice; however, basal food intake was lower in CB(1) knockout mice. Amphetamine decreased feeding in both mouse genotypes. 5 These results suggest that SR141716A may affect the actions of endogenous cannabinoids in regulating appetite or that it may have effects of its own aside from antagonism of cannabinoid effects (e.g., decreased feeding behavior and locomotor stimulation). In either case, these results strongly suggest that CB(1) receptors may play a role in regulation of feeding behavior.     

Genotype-dependent modulation of LY 171555-induced defensive behavior in the mouse

The selective D2 dopamine receptor agonist LY 171555 increased defensive behavior dose dependently, decreased social investigation and activity, and increased immobility in mice of the C57BL/6 (C57) strain interacting with non-aggressive mice of the seme strain. In the same test situation, DBA/2 (DBA) mice did not present any increase in defensive behavior following injection of the same doses of LY 171555, while exhibiting a marked decrease in activity and increased immobility. Mice of the BALB/c strain were less responsive than C57 mice as far as defensive behavior was concerned, and showed decreased activity and social investigation and increased immobility. These results point to a major genetic role in the modulation of social behavior by D2 receptors.     

Central beta 1-adrenergic receptors are involved in CRF-induced defensive withdrawal

Previous studies indicated that peripheral administration of propranolol, a nonselective beta-adrenergic antagonist, attenuated ICV CRF-induced suppression of a conditioned emotional response and defensive withdrawal behavior in rats, suggesting the involvement of a beta-adrenergic receptor in the CRF-induced behavioral changes. The present study was carried out to determine whether central or peripheral beta-adrenergic receptors are involved in CRF-induced defensive withdrawal behavior, and which subtype of beta-adrenergic receptor is involved. l-Propranolol (2.5 mg/kg IP) significantly reversed CRF-induced defensive withdrawal behavior. CGP-12177 (1 mg/kg IP), a beta-adrenergic antagonist with predominant effects on peripheral beta-adrenergic receptors, and ICI 118,551 (0.5 mg/kg IP), a selective beta 2-adrenergic antagonist, had no significant effects on CRF-induced defensive withdrawal. When administered ICV, two selective beta 1-adrenergic antagonists, CGP-20712A (10 micrograms) and atenolol (100 micrograms), significantly antagonized CRF-induced defensive withdrawal. Our results suggest that a central beta 1-adrenergic receptor is involved in CRF-induced defensive withdrawal in rats.     

Differential role of CB1 and TRPV1 receptors on anandamide modulation of defensive responses induced by nitric oxide in the dorsolateral periaqueductal gray

CB1, TRPV1 and NO can regulate glutamate release and modify defensive behaviors in regions related to defensive behavior such as the dorsolateral periaqueductal gray (dlPAG). A possible interaction between the endocannabinoid and nitrergic systems in this area, however, has not been investigated yet. The objective of the present work was to verify if activation of CB1 or TRPV1 receptors could interfere in the flight responses induced in rats by the injection of SIN-1, an NO donor, into the dlPAG. The results showed that local administration of a low dose (5 pmol) of anandamide (AEA) attenuated the flight responses, measured by the total distance moved and maximum speed in an open arena, induced by intra-dlPAG microinjection of SIN-1 (150 nmol). URB597 (0.1 nmol), an inhibitor of anandamide metabolism, produced similar effects. When animals were locally treated with the CB1 receptor antagonist AM251 the effective AEA dose (5 pmol) increased, rather than decreased, the flight reactions induced by SIN1-1. Higher (50–200 nmol) doses of AEA were ineffective and even tended to potentiate the SIN-1 effect. The TRPV1 antagonist capsazepine (CPZ, 30 nmol) prevented SIN-1 effects and attenuated the potentiation of its effect by the higher (200 nmol) AEA dose. The results indicate that AEA can modulate in a dual way the pro-aversive effects of NO in the dlPAG by activating CB1 or TRPV1 receptors.     

Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems

The aim of this work was to study the mechanism of cross-modulation between cannabinoid and opioid systems for analgesia during acute and chronic exposure. Acute coadministration of ineffectual subanalgesic doses of the synthetic cannabinoid CP-55,940 (0.2 mg/kg i.p.) and morphine (2.5 mg/kg i.p.) resulted in significant antinociception. In chronic studies, a low dose of CP-55,940 (0.2 mg/kg, i.p.) that per se did not induce analgesia in naive animals produced a significant degree of antinociception in rats made tolerant to morphine, whereas in rats made tolerant to CP-55,940, morphine challenge did not produce any analgesic response. To identify the mechanism of these asymmetric interactions during chronic treatment, we investigated the functional activity of cannabinoid and μ opioid receptors and their effects on the cyclic AMP (cAMP) cascade. Autoradiographic-binding studies indicated a slight but significant reduction in cannabinoid receptor levels in the hippocampus and cerebellum of morphine-tolerant rats, whereas CP-55,940-stimulated [³⁵S]GTPγS binding showed a significant decrease in receptor/G protein coupling in the limbic area. In CP-55,940 exposed rats, μ opioid receptor binding was significantly raised in the lateral thalamus and periaqueductal gray (PAG), with an increase in DAMGO-stimulated [³⁵S]GTPγS binding in the nucleus accumbens. Finally, we tested the cAMP system's responsiveness to the cannabinoid and opioid in the striatum and dorsal mesencephalon. In vivo chronic morphine did not affect CP-55,940's ability to inhibit forskolin-stimulated cAMP production in vitro and actually induced sensitization in striatal membranes. In contrast, in vivo chronic CP-55,940 desensitized DAMGO's efficacy in inhibiting forskolin-stimulated cAMP production in vitro. The alterations to the cAMP system seem to mirror the behavioral responses, indicating that the two systems may interact at the postreceptor level. This might open up new therapeutic opportunities for relief of chronic pain through cannabinoid–opioid coadministration.     

Multiple mechanisms involved in oxytocin-induced modulation of myometrial contractility

Oxytocin is a small peptide hormone with multiple sites of action in human body. It regulates a large number of reproduction-related processes in all species. Particularly important is its ability to stimulate uterine contractility. This is achieved by multiple mechanisms involving sarcoplasmic reticulum Ca2+ release and sensitization of the contractile apparatus to Ca2+. In this paper, we review the data published by us and other groups on oxytocin-induced modulation of uterine contractility. We conclude that sensitization of contractile apparatus to Ca2+ is the most relevant physiological effect of oxytocin on human myometrium.     

Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity

Olanzapine is one of the most widely prescribed atypical antipsychotic drugs in the treatment of schizophrenia. Besides its well-known side effect on weight gain, it may also impair human parental behavior. In this study, we took a preclinical approach to examine the behavioral effects of olanzapine on rat maternal behavior and investigated the associated neural basis using the c-Fos immunohistochemistry. On postpartum days 6-8, Sprague-Dawley mother rats were given a single injection of sterile water or olanzapine (1.0, 3.0 or 5.0 mg/kg, sc). Maternal behavior was tested 2 h later, after which rats were sacrificed and brain tissues were collected. Ten brain regions that were either implicated in the action of antipsychotic drugs and/or in the regulation of maternal behavior were examined for c-Fos immunoreactivity. Acute olanzapine treatment dose-dependently disrupted various components of maternal behavior (e.g., pup retrieval, pup licking, nest building, crouching) and increased c-Fos immunoreactivity in the medial prefrontal cortex (mPFC), nucleus accumbens shell and core (NAs and NAc), dorsolateral striatum (DLSt), ventral lateral septum (LSv), central amygdala (CeA) and ventral tegmental area (VTA), important brain areas generally implicated in the incentive motivation and reward processing. In contrast, olanzapine treatment did not alter c-Fos in the medial preoptic nucleus (MPN), ventral bed nucleus of the stria terminalis (vBST) and medial amygdala (MeA), the core brain areas directly involved in the mediation of rat maternal behavior. These findings suggest that olanzapine disrupts rat maternal behavior primarily by suppressing incentive motivation and reward processing via its action on the mesocorticolimbic dopamine systems, other limbic and striatal areas, but not by disrupting the core processes involved in the mediation of maternal behavior in particular.     

Hydrogen peroxide and antioxidizing enzymes involved in modulation of transient facilitatory effects of nicotine on neurogenic contractile responses in rat gastric fundus

Nicotine acts as an agonist of nicotinic acetylcholine receptors. Nicotinic acetylcholine receptors play a role in the modulation of neurotransmitter release in both the central and the peripheral nervous system. Moderate reactive oxygen species levels modulate the regulation of physiological functions e.g. neurotransmitter release. Previously in rabbit gastric fundus we demonstrated that nicotine transiently increased neurogenic contraction induced by electrical field stimulation (EFS). In this study we aimed to investigate the effects of hydrogen peroxide (H2O2), antioxidizing enzymes catalase and superoxide dismutase (SOD) on nicotine induced increases at cholinergic neurotransmission in rabbit gastric fundus. Although H2O2 did not alter nicotine induced transient neurogenic contractions at concentrations of 10(-6) and 10(-5) M, at high concentration (10(-4) M) H2O2 inhibited nicotine induced increases. Catalase (500 units/ml), enhanced the effect of nicotine but did not alter nicotine induced transient neurogenic contractions at the concentrations of 100 and 250 units/ml. SOD (75,150 and 225 units/ml) did not alter nicotine induced transient neurogenic contractions. In conclusion, at high concentration H2O2 (10(-4) M) inhibited nicotine's transient ability to augment neurogenic contractions and catalase (500 units/ml) enhanced the effect of nicotine.     

Effects of angiotensin II on behavioral responses of defensive burying paradigm in rats.

The effects of angiotensin II (ATII) administered intracerebroventricularly in male Wistar rats in doses of 0.1, 0.5, and 1.0 micrograms, as well as of ATII (1.0 micrograms) + saralasin (SAR, an analog ATII) (5.0 micrograms), on behavioral responses of the defensive burying paradigm were studied. ATII-treated animals displayed significantly less defensive burying behavior (less time spent in defensive burying and less frequent burying than in vehicle-treated rats) in a dose-dependent manner. SAR at a dose of 5 micrograms did not affect burying behavior significantly; it also did not modify the inhibition effects of ATII on behavioral responses of the defensive burying test. These results provide evidence that ATII can exert anxiolytic actions on central transmitter systems mediating conditioned fear-related behaviors (i.e., defensive burying). The present study suggests that the defensive burying animal model is a rather sensitive test fulfilling the pharmacological criteria of dose-dependent sensitivity for studying the central effects of neuropeptides (e.g., ATII).     

Peripheral cannabinoid CB1 receptors inhibit evoked responses of nociceptive neurones in vivo

We investigated the effect of peripheral administration of a selective cannabinoid CB1 receptor agonist arachidonyl-2-choroethylamide (ACEA), on evoked responses of primary afferents in vivo. Extracellular recordings were made from filaments of the saphenous nerve that responded to noxious mechanical stimulation of their receptive fields and effects of ACEA (30 and 50 microg/100 microl, i.a.) were studied. ACEA significantly inhibited evoked responses, effects that were blocked by co-administration of the cannabinoid CB1 receptor antagonist AM251 (30 microg/100 microl). These results demonstrate a cannabinoid CB1 receptor-mediated inhibition of primary afferent nociceptor excitability and provide further support for a peripheral site of action of cannabinoids.     

Nature of receptors involved in apomorphine responses in pigeons

Apomorphine provokes pecking and emesis in pigeons. These effects are mediated through activation of dopamine receptors. In the present paper the effect of apomorphine on the body temperature was studied and an attempt made to determine whether the receptors mediating pecking, emesis, thermoregulatory effects, etc. were similar or different in their transmitter reactivity.Apomorphine was injected by either an intravenous or intracerebroventricular route. It produced dosedependent pecking and hypothermia. Pecking occurred in the form of a syndrome comprised of preening and visual exploratory movements of the head preceding and following a period of pecking. Large intraventricular doses produced emesis, vocalization, and opisthotonus. When apomorphine was injected intravenously, the dose required was smaller than that required by intraventricular route, suggesting that the receptors involved are located away from the ventricular surface. The reverse was true for hypothermia.The effects of apomorphine were prevented by the dopamine receptor-blocking substance pimozide, but were unaffected by the adrenoceptor-blocking substances phenoxybenzamine and propranolol. Pecking alone was suppressed by 5-HT and facilitated by cyproheptadine.The results indicate that the activation of dopamine receptors mediates the different apomorphine responses, of which only pecking is modulated by activation of tryptamine receptors.     

Ozone-induced modulation of cell-mediated immune responses in the lungs

Most pulmonary immunotoxicology studies of ambient pollutants have been broadly designed to discern if overall humoral or cell-mediated immunity (CMI) was altered; few have assessed effects on particular aspects of immune function. We hypothesized that effects from ozone (O3) exposure on pulmonary CMI are linked in part to changes in local immune cell capacities to form and/or to interact with immunoregulatory cytokines. Rats exposed to 0.1 or 0.3 ppm O3 4 h/day 5 days/week, for 1 or 3 weeks were assessed for resistance to, and pulmonary clearance of, a subsequent Listeria monocytogenes challenge. In situ cytokine release and immune cell profiles were also analyzed at different stages of the antilisterial response. Although O3 exposure modulated CMI, effects were not consistently concentration- or duration-dependent. Exposure did not effect cumulative mortality from infection, but induced concentration-related effects upon morbidity onset and persistence. All 1-week exposed rats had listeric burdens trending higher than controls; 0.3 ppm rats displayed continual burden increases rather than any onset of resolution. Rats exposed for 3 weeks had no O3-related changes in clearance. No exposure-related effect on neutrophil or pulmonary macrophage (PAM) numbers or percentages was noted. Bacterial burden analyses with respect to cell type showed that Listeria:PAM ratios in 0.3 ppm rats ultimately became greatest compared to all other rats. In situ IL-1alpha and TNFalpha levels were consistently higher in O3-exposed rats. All rats displayed increasing in situ IFNgamma levels as infection progressed, but no constant relationship was evident between IFNgamma and initial IL-1alpha/TNFalpha levels in O3-exposed hosts. It seems that short-term (i.e., 1 week) repeated O3 exposures imparted more effects upon CMI than a more prolonged (i.e., 3 week) regimen, with effects manifesting at the level of the PAM and in the cytokine network responsible for immunoactivation.